On-demand Webinar
Co-organized with BaiPharm
4:00pm-4:40pm CET / 10:00am-10:40am EST
Generic drugs account for more than 90% of the marketed drugs in China. In 2012, China initiated the
equivalence evaluation plan to require that generics should be equivalent to originator drugs in
quality and efficacy. In 2016, China started implementing equivalence evaluation requirements for
chemical drugs’ oral solid dosage forms. In 2020, the evaluation expanded to chemical
injections.
Quality and therapeutic equivalence evaluation pushes pharmaceutical companies to
develop and produce generic drugs of higher quality. If the generics with high levels of quality and
efficacy pass the equivalence evaluation, they will be deemed clinical substitutes for originator
drugs. With lower prices, the generics have more advantages than originator drugs in public medical
institutions’ volume-based procurements. Thus, generics grow to take higher market
shares.
This webinar aims to help pharmaceutical companies understand China’s regulatory
requirements for quality and therapeutic equivalence evaluation, its market impacts, and the data on
accepted and approved applications for the equivalence evaluation.
Grace Wang
Regulatory Analyst
BaiPharm
Grace Wang is a regulatory analyst specializing in pharmaceutical regulations and market trends. She provides insights to help international pharma companies with China market access. Her areas of focus include DMF filing, new drug application, pharmacovigilance, and the volume-based procurement policy.
Regulatory Requirements of Quality and Therapeutic Equivalence Evaluations of Generic Drugs
How Equivalence Evaluation Impacts Pharma Market
Accepted Applications for Equivalence Evaluation
Approved Applications for Equivalence Evaluation
Jennifer Yang
+86 -21 3339 2533
jennifer.yang@imsinoexpo.com
FEATURED
Product:
OUR